SAN FRANCISCO, Oct. 16, 2017 /PRNewswire/ -- OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, today announced that Nikhilesh N. Singh, Ph.D., President and Chief Executive Officer, will present at the 16th Annual BIO Investor Forum, being held October 17-18, 2017, in San Francisco.
Date: October 17, 2017
Time: 02:15 – 02:28 p.m. PT
Location: The Westin St. Francis, Yorkshire Room
A copy of the presentation will be available at www.orphomed.com.
About OrphoMed, Inc.
OrphoMed is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class dimer therapeutics for patients with gastrointestinal disorders. Leveraging its proprietary dimer platform technology, OrphoMed is advancing ORP-101, a potential best-in-class buprenorphine dimer in clinical development for the treatment of IBS-D, and its pipeline of additional dimer conjugates. For more information please visit www.orphomed.com.
SOURCE OrphoMed, Inc.